Cargando…

Glucocorticoids in the treatment of acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is characterized by local inflammation and an intense systemic inflammatory reaction. Glucocorticoid administration has been suggested due to their anti-inflammatory properties. However, results from the initial studies of glucocorticoids in ARDS, which eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Roche-Campo, F., Aguirre-Bermeo, H., Mancebo, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117829/
https://www.ncbi.nlm.nih.gov/pubmed/32288728
http://dx.doi.org/10.1007/s13546-011-0316-1
_version_ 1783514450460934144
author Roche-Campo, F.
Aguirre-Bermeo, H.
Mancebo, J.
author_facet Roche-Campo, F.
Aguirre-Bermeo, H.
Mancebo, J.
author_sort Roche-Campo, F.
collection PubMed
description Acute respiratory distress syndrome (ARDS) is characterized by local inflammation and an intense systemic inflammatory reaction. Glucocorticoid administration has been suggested due to their anti-inflammatory properties. However, results from the initial studies of glucocorticoids in ARDS, which evaluated high-dose and short-term treatments, were negative. More recent studies have evaluated the effect of lower doses of glucocorticoids administered over longer periods, but the results thus far have been inconclusive.
format Online
Article
Text
id pubmed-7117829
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-71178292020-04-03 Glucocorticoids in the treatment of acute respiratory distress syndrome Roche-Campo, F. Aguirre-Bermeo, H. Mancebo, J. Reanimation Enseignement Supérieur en Réanimation Acute respiratory distress syndrome (ARDS) is characterized by local inflammation and an intense systemic inflammatory reaction. Glucocorticoid administration has been suggested due to their anti-inflammatory properties. However, results from the initial studies of glucocorticoids in ARDS, which evaluated high-dose and short-term treatments, were negative. More recent studies have evaluated the effect of lower doses of glucocorticoids administered over longer periods, but the results thus far have been inconclusive. Springer-Verlag 2011-10-25 2012 /pmc/articles/PMC7117829/ /pubmed/32288728 http://dx.doi.org/10.1007/s13546-011-0316-1 Text en © Société de réanimation de langue française (SRLF) and Springer-Verlag France 2011 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Enseignement Supérieur en Réanimation
Roche-Campo, F.
Aguirre-Bermeo, H.
Mancebo, J.
Glucocorticoids in the treatment of acute respiratory distress syndrome
title Glucocorticoids in the treatment of acute respiratory distress syndrome
title_full Glucocorticoids in the treatment of acute respiratory distress syndrome
title_fullStr Glucocorticoids in the treatment of acute respiratory distress syndrome
title_full_unstemmed Glucocorticoids in the treatment of acute respiratory distress syndrome
title_short Glucocorticoids in the treatment of acute respiratory distress syndrome
title_sort glucocorticoids in the treatment of acute respiratory distress syndrome
topic Enseignement Supérieur en Réanimation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117829/
https://www.ncbi.nlm.nih.gov/pubmed/32288728
http://dx.doi.org/10.1007/s13546-011-0316-1
work_keys_str_mv AT rochecampof glucocorticoidsinthetreatmentofacuterespiratorydistresssyndrome
AT aguirrebermeoh glucocorticoidsinthetreatmentofacuterespiratorydistresssyndrome
AT manceboj glucocorticoidsinthetreatmentofacuterespiratorydistresssyndrome